After finishing at $176.27 in the prior trading day, Abbvie Inc (NYSE: ABBV) closed at $177.50, up 0.70%. In other words, the price has increased by $+1.23 from its previous closing price. On the day, 5723104 shares were traded.
Ratios:
Our goal is to gain a better understanding of ABBV by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 24.47 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.24. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 0.87. In the meantime, Its Debt-to-Equity ratio is 5.80 whereas as Long-Term Debt/Eq ratio is at 5.11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 18 ’24 when Stewart Jeffrey Ryan sold 58,949 shares for $178.79 per share. The transaction valued at 10,539,508 led to the insider holds 60,941 shares of the business.
RICHMOND TIMOTHY J. sold 75,680 shares of ABBV for $13,415,503 on Mar 01 ’24. The EVP, CHIEF HR OFFICER now owns 13,837 shares after completing the transaction at $177.27 per share. On Feb 29 ’24, another insider, Michael Robert A., who serves as the PRES & CHIEF OPERATING OFFICER of the company, sold 68,879 shares for $176.45 each. As a result, the insider received 12,153,957 and left with 98,645 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 312.11B and an Enterprise Value of 358.68B. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 65.25, and their Forward P/E ratio for the next fiscal year is 14.54. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 19.91. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.77 while its Price-to-Book (P/B) ratio in mrq is 30.26. Its current Enterprise Value per Revenue stands at 6.60 whereas that against EBITDA is 20.89.
Stock Price History:
Over the past 52 weeks, ABBV has reached a high of $182.89, while it has fallen to a 52-week low of $130.96. The 50-Day Moving Average of the stock is 172.93, while the 200-Day Moving Average is calculated to be 152.49.
Shares Statistics:
The stock has traded on average 5.54M shares per day over the past 3-months and 7.99M shares per day over the last 10 days, according to various share statistics. A total of 1.77B shares are outstanding, with a floating share count of 1.76B. Insiders hold about 0.11% of the company’s shares, while institutions hold 71.99% stake in the company. Shares short for ABBV as of Feb 29, 2024 were 14.27M with a Short Ratio of 2.58, compared to 13.72M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.81% and a Short% of Float of 0.81%.
Dividends & Splits
In the trailing 12 months, ABBV’s forward annual dividend rate was 5.99, compared to 5.99 this year. Against a Trailing Annual Dividend Yield of 3.40%, it implies a Forward Annual Dividend Yield of 3.49%. The stock’s 5-year Average Dividend Yield is 4.45.
Earnings Estimates
Its stock is currently analyzed by 16 different market analysts. On average, analysts expect EPS of $2.34 for the current quarter, with a high estimate of $2.41 and a low estimate of $2.3, while EPS last year was $2.46. The consensus estimate for the next quarter is $2.81, with high estimates of $2.93 and low estimates of $2.62.
Analysts are recommending an EPS of between $11.56 and $10.85 for the fiscal current year, implying an average EPS of $11.19. EPS for the following year is $12.21, with 25 analysts recommending between $13.05 and $11.5.
Revenue Estimates
14 analysts predict $11.97B in revenue for the current quarter. It ranges from a high estimate of $12.59B to a low estimate of $11.86B. As of the current estimate, Abbvie Inc’s year-ago sales were $12.22B, an estimated decrease of -2.10% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $13.52B, a decrease of -2.50% less than the figure of -$2.10% in the same quarter last year. There is a high estimate of $13.82B for the next quarter, whereas the lowest estimate is $12.99B.
A total of 26 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $55.38B, while the lowest revenue estimate was $53.86B, resulting in an average revenue estimate of $54.54B. In the same quarter a year ago, actual revenue was $54.32B, up 0.40% from the average estimate. Based on 25 analysts’ estimates, the company’s revenue will be $57.9B in the next fiscal year. The high estimate is $60.8B and the low estimate is $55.72B. The average revenue growth estimate for next year is up 6.20% from the average revenue estimate for this year.
